Page 73 - Priority Review News Today

The FDA has accepted for review two sNDAs for Prevymis (letermovir).

2022: Successful transformation into a commercial stage company "2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for... | February 23, 2023

/PRNewswire/ -- Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant),...

 FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection Paris and Stockholm – February 23, 2023 – The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-V...

The FDA has accepted for Priority Review the BLA for RSVpreF (PF-06928316), a bivalent RSV vaccine candidate for administration to pregnant individuals.

The FDA has accepted for review the BLA for aflibercept 8mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA...

The FDA has accepted for Priority Review the BLA for pozelimab for the treatment of patients 1 year of age and older with CHAPLE disease.

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA...

The FDA has accepted for Priority Review the BLA for elranatamab for the treatment of patients with relapsed or refractory multiple myeloma.